Declare

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Declare [NCT01730534]

Description: This study is being carried out to see if dapagliflozin when added to a patients current anti-diabetes therapy is effective in reducing cardiovascular events such as myocardial infarction (MI) (heart attack), ischemic stroke, and cardiovascular (CV) related death, compared with placebo (inactive study medication).

Drug: Dapagliflozin 10 mg; Drug: Placebo tablet


 

Primary Investigator: Kereiakes

Drug/Device Information
Study to evaluate whether treatment with Dapagliflozin reduces major adverse cardiovascular events in patients with Type 2 Diabetes and with either known cardiovascular disease OR
At least two risk factors for cardiovascular disease in addition to Type 2 Diabetes
Dapagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor
AstraZeneca AB